Stifel Financial Corp Cytom X Therapeutics, Inc. Transaction History
Stifel Financial Corp
- $93.2 Billion
- Q3 2024
A detailed history of Stifel Financial Corp transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 46,100 shares of CTMX stock, worth $38,724. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,100
Previous 47,100
2.12%
Holding current value
$38,724
Previous $57,000
5.26%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CTMX
# of Institutions
72Shares Held
49.4MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$6.56 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.39 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.34 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$4.04 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$2.6 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $55.4M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...